<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00552110</url>
  </required_header>
  <id_info>
    <org_study_id>P04500</org_study_id>
    <nct_id>NCT00552110</nct_id>
  </id_info>
  <brief_title>Study of Mometasone Furoate Nasal Spray and Oxymetazoline Nasal Spray Given Together Once A Day To Treat Seasonal Allergic Rhinitis (P04500)</brief_title>
  <official_title>Efficacy and Safety of Concurrent Administration of Mometasone Furoate Nasal Spray (MFNS) and Oxymetazoline Nasal Spray Administered Once Daily (QD) vs. Oxymetazoline Twice Daily (BID), Mometasone Furoate QD, and Placebo in the Treatment of Subjects With Seasonal Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quintiles, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the efficacy of the combination of
      mometasone furoate nasal spray (MFNS) and oxymetazoline nasal spray (OXY) given together once
      a day in treating subjects with seasonal allergic rhinitis (SAR) in relieving symptoms
      including nasal congestion. The secondary objectives of this study are to evaluate the
      potential of the combination to produce tachyphylaxis and/or rebound congestion, and to
      evaluate the safety of the combination.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in AM/PM Instantaneous Total Nasal Symptom Score (NOW TNSS) Averaged Over Days 1 to 15</measure>
    <time_frame>15 days of treatment</time_frame>
    <description>Subjects scored severity of rhinorrhea, nasal congestion/stuffiness, nasal itching, and sneezing at the time of evaluation (NOW) using an ordinal scale from 0 = none to 3 = severe. Evaluations were performed daily in the morning (AM) and evening (PM). For each evaluation, individual symptom scores were summed to a TNSS, which was then averaged for a single score across the 15 day treatment period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Standardized Area Under the Curve From 0 to 4 Hours [AUC(0-4 hr)] of the Change From Baseline to Hour 4 on Day 1 in Nasal Congestion Score</measure>
    <time_frame>from baseline to hour 4 on Day 1</time_frame>
    <description>Subjects scored nasal congestion/stuffiness using an ordinal scale from 0 = none to 3 = severe. Baseline was the average of the scores assessed every 15 minutes for 1 hour prior to dosing on Day 1. After dosing on Day 1, congestion was scored every 15 minutes for the 1st hour and every 30 minutes for the next 3 hours. Area under the curve (AUC) was calculated using the trapezoid rule, then standardization achieved by dividing the calculation by 4 hours. Treatment comparisons were examined using the standardized AUC(0-4 hr) of the change from baseline to hour 4 on Day 1.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">707</enrollment>
  <condition>Seasonal Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Combination1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mometasone Furoate nasal spray (MFNS) with oxymetazoline nasal spray (OXY) 1 spray once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MFNS with OXY 3 sprays once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mometasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MFNS once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxymetazoline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>OXY twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo nasal spray</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OXY combination: mometasone furoate nasal spray (MFNS) and oxymetazoline nasal spray (OXY)</intervention_name>
    <description>MFNS 2 sprays per nostril with OXY 1 spray per nostril once daily x 2 weeks. Matching placebo to MFNS given every evening (PM).</description>
    <arm_group_label>Combination1</arm_group_label>
    <other_name>MFNS + OXY combination</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OXY combination: mometasone furoate nasal spray (MFNS) and oxymetazoline nasal spray (OXY)</intervention_name>
    <description>MFNS 2 sprays per nostril with OXY 3 sprays per nostril once daily x 2 weeks. Matching placebo to MFNS given every evening.</description>
    <arm_group_label>Combination3</arm_group_label>
    <other_name>MFNS + OXY combination assessing a different dose (ie, number of sprays) from that used in Group 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mometasone furoate nasal spray (MFNS) once daily</intervention_name>
    <description>MFNS 2 sprays per nostril once daily x 2 weeks. Matching placebo to MFNS given every morning (AM) and every evening.</description>
    <arm_group_label>Mometasone</arm_group_label>
    <other_name>MFNS QD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxymetazoline nasal spray (OXY) twice daily</intervention_name>
    <description>OXY 2 sprays per nostril twice daily x 2 weeks. Matching placebo to MFNS given every morning.</description>
    <arm_group_label>Oxymetazoline</arm_group_label>
    <other_name>OXY BID</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo to MFNS given every morning and every evening x 2 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be 12 years of age or older, of either sex, and of any race.

          -  Must have at least a 2-year documented history of SAR which exacerbates during the
             time period over which the subject will be participating.

          -  Must have a documented (within the past 12 months) positive skin-prick test response
             to an appropriate seasonal allergen appropriate to the geographical vicinity in which
             the study is being carried out and over the period of time the subject is
             participating.

          -  Must be clinically symptomatic at the Screening and Baseline Visits.

          -  Must be in general good health as confirmed by routine clinical and laboratory testing
             and electrocardiogram results.

          -  Must be free of any clinically significant disease, other than SAR, which would
             interfere with the study evaluations.

          -  Must be willing to give written informed consent and must be able to adhere to dosing
             and visit schedules and study requirements.

          -  Female subjects of child-bearing potential must have a negative serum pregnancy test
             at screening. Nonsterile and premenopausal female subjects must be using a medically
             acceptable method of birth control prior to screening and during the entire study.

          -  Must have the ability to transmit electronic diary data on a regular basis.

        Exclusion Criteria:

          -  A subject with a history of anaphylaxis and/or other severe local reaction(s) to skin
             testing.

          -  A subject with asthma who requires chronic use of inhaled or systemic corticosteroids.

          -  A subject with current or history of frequent, clinically significant sinusitis or
             chronic purulent postnasal drip.

          -  A subject with rhinitis medicamentosa.

          -  A subject with glaucoma and/or increased intraocular pressure.

          -  A subject who has nasal structural abnormalities, including large nasal polyps and
             marked septal deviations, which significantly interfere with nasal air flow.

          -  A subject who, in the opinion of the investigator, is dependent on nasal, oral, or
             ocular decongestants, nasal topical antihistamines, or nasal steroids.

          -  A pregnant or nursing female.

          -  A subject with current evidence of clinically significant hematopoietic,
             cardiovascular, hepatic, renal, neurologic, psychiatric, pulmonary, autoimmune
             disease, or other disease that precludes the subject's participation in the study.
             Particular attention should be given to exclude subjects with conditions that would
             currently interfere with the absorption, distribution, metabolism, or excretion of the
             study drug or interfere with the subject's ability to complete or reliably complete
             the diaries.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ariel A Teper, MD</last_name>
    <role>Study Director</role>
    <affiliation>Schering-Plough</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Meltzer EO, Bernstein DI, Prenner BM, Berger WE, Shekar T, Teper AA. Mometasone furoate nasal spray plus oxymetazoline nasal spray: short-term efficacy and safety in seasonal allergic rhinitis. Am J Rhinol Allergy. 2013 Mar-Apr;27(2):102-8. doi: 10.2500/ajra.2013.27.3864.</citation>
    <PMID>23562197</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2007</study_first_submitted>
  <study_first_submitted_qc>October 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2007</study_first_posted>
  <results_first_submitted>May 15, 2009</results_first_submitted>
  <results_first_submitted_qc>May 15, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 8, 2009</results_first_posted>
  <last_update_submitted>March 13, 2017</last_update_submitted>
  <last_update_submitted_qc>March 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mometasone Furoate</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>Phenylephrine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Combination1</title>
          <description>Mometasone Furoate nasal spray (MFNS) with oxymetazoline nasal spray (OXY) 1 spray once daily</description>
        </group>
        <group group_id="P2">
          <title>Combination3</title>
          <description>MFNS with OXY 3 sprays once daily</description>
        </group>
        <group group_id="P3">
          <title>Mometasone</title>
          <description>MFNS once daily</description>
        </group>
        <group group_id="P4">
          <title>Oxymetazoline</title>
          <description>OXY twice daily</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>Placebo nasal spray</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="146">One subject was excluded from the intent to treat population because there was no record of dosing.</participants>
                <participants group_id="P2" count="139"/>
                <participants group_id="P3" count="139"/>
                <participants group_id="P4" count="141">One subject was excluded from the intent to treat population because there was no record of dosing.</participants>
                <participants group_id="P5" count="142"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="142"/>
                <participants group_id="P2" count="134"/>
                <participants group_id="P3" count="137"/>
                <participants group_id="P4" count="133"/>
                <participants group_id="P5" count="133"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Serious or Life-Threatening AE</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failed to Comply With Study Requirements</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawn per Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Use of Prohibited Medication</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Delay of Study due to Relabeling</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Increased Blood Pressure at Visit 2</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Nonserious Adverse Event (AE)</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Combination1</title>
          <description>Mometasone Furoate nasal spray (MFNS) with oxymetazoline nasal spray (OXY) 1 spray once daily</description>
        </group>
        <group group_id="B2">
          <title>Combination3</title>
          <description>MFNS with OXY 3 sprays once daily</description>
        </group>
        <group group_id="B3">
          <title>Mometasone</title>
          <description>MFNS once daily</description>
        </group>
        <group group_id="B4">
          <title>Oxymetazoline</title>
          <description>OXY twice daily</description>
        </group>
        <group group_id="B5">
          <title>Placebo</title>
          <description>Placebo nasal spray</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="145"/>
            <count group_id="B2" value="139"/>
            <count group_id="B3" value="139"/>
            <count group_id="B4" value="140"/>
            <count group_id="B5" value="142"/>
            <count group_id="B6" value="705"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Intention to treat population: all randomized subjects who had taken at least one dose of study drug</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="135"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="132"/>
                    <measurement group_id="B4" value="131"/>
                    <measurement group_id="B5" value="127"/>
                    <measurement group_id="B6" value="649"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>Intention to treat population: all randomized subjects who had taken at least one dose of study drug</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="101"/>
                    <measurement group_id="B4" value="95"/>
                    <measurement group_id="B5" value="89"/>
                    <measurement group_id="B6" value="471"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="45"/>
                    <measurement group_id="B5" value="53"/>
                    <measurement group_id="B6" value="234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in AM/PM Instantaneous Total Nasal Symptom Score (NOW TNSS) Averaged Over Days 1 to 15</title>
        <description>Subjects scored severity of rhinorrhea, nasal congestion/stuffiness, nasal itching, and sneezing at the time of evaluation (NOW) using an ordinal scale from 0 = none to 3 = severe. Evaluations were performed daily in the morning (AM) and evening (PM). For each evaluation, individual symptom scores were summed to a TNSS, which was then averaged for a single score across the 15 day treatment period.</description>
        <time_frame>15 days of treatment</time_frame>
        <population>Intention to treat (ITT): all randomized subjects who had taken at least one dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Combination1</title>
            <description>Mometasone Furoate nasal spray (MFNS) with oxymetazoline nasal spray (OXY) 1 spray once daily</description>
          </group>
          <group group_id="O2">
            <title>Combination3</title>
            <description>MFNS with OXY 3 sprays once daily</description>
          </group>
          <group group_id="O3">
            <title>Mometasone</title>
            <description>MFNS once daily</description>
          </group>
          <group group_id="O4">
            <title>Oxymetazoline</title>
            <description>OXY twice daily</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo nasal spray</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in AM/PM Instantaneous Total Nasal Symptom Score (NOW TNSS) Averaged Over Days 1 to 15</title>
          <description>Subjects scored severity of rhinorrhea, nasal congestion/stuffiness, nasal itching, and sneezing at the time of evaluation (NOW) using an ordinal scale from 0 = none to 3 = severe. Evaluations were performed daily in the morning (AM) and evening (PM). For each evaluation, individual symptom scores were summed to a TNSS, which was then averaged for a single score across the 15 day treatment period.</description>
          <population>Intention to treat (ITT): all randomized subjects who had taken at least one dose of study drug</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="138"/>
                <count group_id="O3" value="139"/>
                <count group_id="O4" value="139"/>
                <count group_id="O5" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.29" spread="0.209"/>
                    <measurement group_id="O2" value="-3.36" spread="0.216"/>
                    <measurement group_id="O3" value="-2.97" spread="0.213"/>
                    <measurement group_id="O4" value="-2.44" spread="0.215"/>
                    <measurement group_id="O5" value="-1.90" spread="0.209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: the concurrent administration of MFNS and OXY once daily has the same mean change from baseline in AM/PM NOW TNSS as that of OXY twice daily.
Power calculation: The target randomization of 875 subjects (175 subjects per treatment arm) was needed to detect a treatment difference of 0.8 point or more in change from baseline in AM/PM NOW TNSS, with a two-sided alpha of 0.05 and 90% power, assuming a pooled standard deviation of 2.3 points.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>Multiplicity for multiple treatment comparisons was not adjusted.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Analysis of Covariance (ANCOVA); classification variables: treatment, center, dosing sequence (stratification variable); covariate: baseline score</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: the concurrent administration of MFNS and OXY once daily has the same mean change from baseline in AM/PM NOW TNSS as that of OXY twice daily.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: the administration of MFNS once daily has the same mean change from baseline in AM/PM NOW TNSS as that of placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Standardized Area Under the Curve From 0 to 4 Hours [AUC(0-4 hr)] of the Change From Baseline to Hour 4 on Day 1 in Nasal Congestion Score</title>
        <description>Subjects scored nasal congestion/stuffiness using an ordinal scale from 0 = none to 3 = severe. Baseline was the average of the scores assessed every 15 minutes for 1 hour prior to dosing on Day 1. After dosing on Day 1, congestion was scored every 15 minutes for the 1st hour and every 30 minutes for the next 3 hours. Area under the curve (AUC) was calculated using the trapezoid rule, then standardization achieved by dividing the calculation by 4 hours. Treatment comparisons were examined using the standardized AUC(0-4 hr) of the change from baseline to hour 4 on Day 1.</description>
        <time_frame>from baseline to hour 4 on Day 1</time_frame>
        <population>Intention to treat: all randomized subjects who had taken at least one dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Combination1</title>
            <description>Mometasone Furoate nasal spray (MFNS) with oxymetazoline nasal spray (OXY) 1 spray once daily</description>
          </group>
          <group group_id="O2">
            <title>Combination3</title>
            <description>MFNS with OXY 3 sprays once daily</description>
          </group>
          <group group_id="O3">
            <title>Mometasone</title>
            <description>MFNS once daily</description>
          </group>
          <group group_id="O4">
            <title>Oxymetazoline</title>
            <description>OXY twice daily</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo nasal spray</description>
          </group>
        </group_list>
        <measure>
          <title>Standardized Area Under the Curve From 0 to 4 Hours [AUC(0-4 hr)] of the Change From Baseline to Hour 4 on Day 1 in Nasal Congestion Score</title>
          <description>Subjects scored nasal congestion/stuffiness using an ordinal scale from 0 = none to 3 = severe. Baseline was the average of the scores assessed every 15 minutes for 1 hour prior to dosing on Day 1. After dosing on Day 1, congestion was scored every 15 minutes for the 1st hour and every 30 minutes for the next 3 hours. Area under the curve (AUC) was calculated using the trapezoid rule, then standardization achieved by dividing the calculation by 4 hours. Treatment comparisons were examined using the standardized AUC(0-4 hr) of the change from baseline to hour 4 on Day 1.</description>
          <population>Intention to treat: all randomized subjects who had taken at least one dose of study drug</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="138"/>
                <count group_id="O3" value="139"/>
                <count group_id="O4" value="139"/>
                <count group_id="O5" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.80" spread="0.056"/>
                    <measurement group_id="O2" value="-0.92" spread="0.057"/>
                    <measurement group_id="O3" value="-0.63" spread="0.057"/>
                    <measurement group_id="O4" value="-1.06" spread="0.057"/>
                    <measurement group_id="O5" value="-0.57" spread="0.056"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: the concurrent administration of MFNS and OXY once daily has the same standardized AUC(0-4 hr) of the change from baseline in nasal congestion score as that of MFNS once daily.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.021</p_value>
            <p_value_desc>Multiplicity for multiple treatment comparisons was not adjusted.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA; classification variables: treatment, center, dosing sequence (stratification variable); covariate: baseline score</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: the concurrent administration of MFNS and OXY once daily has the same standardized AUC (0-4hr) of the change from baseline in nasal congestion score as that of MFNS once daily</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: the administration of OXY twice daily has the same standardized AUC(0-4 hr) of the change from baseline in nasal congestion score as that of placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Combination1</title>
          <description>Mometasone Furoate nasal spray (MFNS) with oxymetazoline nasal spray (OXY) 1 spray once daily</description>
        </group>
        <group group_id="E2">
          <title>Combination3</title>
          <description>MFNS with OXY 3 sprays once daily</description>
        </group>
        <group group_id="E3">
          <title>Mometasone</title>
          <description>MFNS once daily</description>
        </group>
        <group group_id="E4">
          <title>Oxymetazoline</title>
          <description>OXY twice daily</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>Placebo nasal spray</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrooesophageal Reflux Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
              <event>
                <sub_title>Oesophageal Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="140"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="145"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="139"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="139"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="140"/>
                <counts group_id="E5" events="8" subjects_affected="8" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Subject symptom data were not collected during the post-treatment period. Thus, daily diary data for rebound congestion was not analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

